Biotech Values

[DewDiligence]

ABT’s new revenue breakdown among its four business segments:

Nutrition products (adult & pediatric): 34%
Medical devices: 27%
Diagnostics: 23%
Branded-generic drugs: 16%

ABT’s branded-generics segment used to be the largest of the four, but a portion of this business was recently sold to MYL in return for a 22% equity stake (#msg-110385639). During the next few years, new acquisitions in emerging markets will likely increase ABT’s branded-generics segment back to 20-25% of total corporate sales.

All told, ABT derives ~70% of sales from outside the US, one of the highest proportions of any S&P 500 company.

Source: today’s Cowen webcast.